Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year

Reports Q1 revenue $10.8M, consensus $4.05M. “During the first quarter, we continued to execute on our two clinical stage in vivo gene editing programs. We advanced PBGENE-HBV into new cohorts in the ELIMINATE-B trial and drove PBGENE-DMD through Investigational New Drug approval and activated our first clinical site as we prepare to dose the first patient in the FUNCTION-DMD trial,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences (DTIL). “We remain focused on disciplined execution in 2026 as we generate additional clinical data from the ELIMINATE-B trial and enroll more sites and patients in the FUNCTION-DMD trial. We believe our ARCUS platform and targeted development strategy position us to deliver multiple important clinical and operational milestones this year.”